Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

NCT ID: NCT00619268

Last Updated: 2013-02-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2012-02-29

Brief Summary

The TORAVA trial is designed to evaluate the progression-free rate at 48 weeks of a combination of Torisel® and Avastin® given at first-line treatment in patients with metastatic renal cancer.

Eligible patients will be randomly assigned, in a 2:1:1 ratio, to either Avastin® + Torisel®, or Sutent® or IFN+Avastin®.

Detailed Description

This is a phase II, open label, randomized, parallel group, multicenter study evaluating first-line treatment of patients with metastatic renal cancer using a combination of Torisel® administered intravenously as 25 mg every week and Avastin® administered intravenously as 10 mg/kg every 2 weeks.

Two standard arms with either Sutent® (given orally as 50 mg once daily during 4 weeks, followed by 2 weeks off) or a combination of Avastin® (administered intravenously as 10 mg/kg every 2 weeks) and Interferon (IFN, administered subcutaneously as 9 MU three times a week) will be used to validate the results obtained in the experimental arm (randomization eliminates selection biases), and to assess Sutent® efficacy rate on a more representative population than in Motzer's trial (Motzer NEJM 2007).

The study is not designed to provide head-to-head comparisons between the experimental arm (Avastin® + Torisel®) and the two standard arms (Sutent® and IFN + Avastin®). Randomization will be used as a tool for allocating patients evenly into the 3 treatment arms to ensure proper balance of prognostic factors. If the progression-free rates observed in randomly assigned control patients are inconsistent with historical data, it may be a warning that the results observed for the experimental arm should be viewed with caution. Patients will be randomly assigned to either option in a 2:1:1 ratio (half less patients in the standard arms used only as historical comparators), and stratified according to inclusion center and performance status (ECOG PS 0 vs. 1 vs. 2).

In the absence of severe toxicity, treatment will be continued until documented progression of the disease (RECIST criteria). Toxicity will be evaluated throughout the treatment period and until disappearance or stabilization of the side effect(s). In case of progression, each investigator makes his/her own treatment decisions, provided that all anti-cancer treatments given to the patients within the frame of the study are reported, as well as their results.

Response rates will be assessed between weeks 11-12, 23-24, 35-36, 47-48 in the first year (corresponding to 2 cycles of Sutent®) and every 3 months afterwards until treatment stop, or until patient death or end of clinical data collection.

Conditions

Metastatic Renal Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Group Type: EXPERIMENTAL

Temsirolimus

Intervention Type: DRUG

25 mg once per week administered intravenously

Bevacizumab

Intervention Type: DRUG

10 mg/kg \* 1 time /2 weeks administered intravenously

B

Group Type: ACTIVE_COMPARATOR

Sunitinib

Intervention Type: DRUG

50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off

C

Group Type: ACTIVE_COMPARATOR

Bevacizumab

Intervention Type: DRUG

10 mg/kg \* 1 time /2 weeks administered intravenously

Interferon alpha-2a

Intervention Type: DRUG

Administered subcutaneously as 9 MU three times per week

Interventions

Temsirolimus

25 mg once per week administered intravenously

Intervention Type: DRUG

Bevacizumab

10 mg/kg \* 1 time /2 weeks administered intravenously

Intervention Type: DRUG

Sunitinib

50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off

Intervention Type: DRUG

Interferon alpha-2a

Administered subcutaneously as 9 MU three times per week

Intervention Type: DRUG

Other Intervention Names

Torisel®; Avastin®; Sutent®; Roféron®

Eligibility Criteria

Inclusion Criteria

• Male or female patients>= 18 years of age;
• Patients with histological or cytological evidence of metastatic renal cell carcinoma mostly of all type,except for papillary;
• No prior systemic treatment (chemotherapy, immunotherapy, anti-angiogenic drugs, or treatment under evaluation) for metastatic renal cancer;
• No brain metastases revealed by MRI or CT-scan within 28 days prior to randomization. Patients with a history of brain metastases treated by surgery +/- radiation therapy can be included if they have normal brain MRI;
• E.C.O.G performance status =<2;
• At least one measurable lesion using the RECIST criteria;
• Blood tests and renal and liver functions in the normal range with, in the 7 days prior to study entry, blood or serum values as follows:

Hemoglobin > 8g/dl; Neutrophil count > 1500*10exp9/L; Platelets > 100*10exp9/L; Serum creatinine < 200µmol/L; Total Bilirubin < 1.5 times upper limit of normal; ALT and AST < 2.5 times upper limit of normal or < 5 ULN for patients with liver metastases, PT or INR < 1.5 times upper limit of normal in the absence of anticoagulant therapy;

• Absence of proteinuria confirmed by urinary dipstick test
• Fertile women must use effective means of contraception
• Mandatory affiliation with a healthy security insurance
• Signed written informed consent.

Exclusion Criteria

• Patient with pure papillary renal cell carcinoma
• Prior systemic treatment for metastatic renal cancer
• History of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization
• Evidence of brain metastasis by computerized tomographic scan or MRI in the 28 days prior to randomization. Patients with history of brain metastases treated by exclusive brain therapy are not allowed to participate, even if brain MRI is normal
• Significant cardiovascular disease or uncontrolled hypertension while receiving appropriate medication (>= 160 mm Hg systolic and/or >= 90 mm Hg diastolic)
• Hepatic affection like chronic advanced hepatitis, liver cirrhosis or chronic hepatitis recently treated or in process of treatment by immunosuppressive agents, hepatitis auto-immune or history of auto-immune disease
• Major surgical procedure, open biopsy, or serious non healing wound within 28 days prior to randomization
• Uncontrolled hypercalcemia while receiving appropriate treatment
• Uncontrolled hypercholesterolemia or hypertriglyceridemia
• Patient under anti-vitamin K therapy
• Patient under strong CYP3A4 inhibitors
• Patient with severe neuropsychiatric disorder (or comitial crises)
• Patient included in another clinical trial, except for supportive care trials
• Pregnant or lactating women (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Leon Berard

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sylvie NEGRIER, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Centre Leon Berard

Bernard ESCUDIER, MD

Role: PRINCIPAL_INVESTIGATOR

Gustave Roussy, Cancer Campus, Grand Paris

Locations

Centre Paul Papin

Angers, , France

Centre Hospitalier Universitaire de Besançon

Besançon, , France

Centre Hospitalier Universitaire de Bordeaux - Hôpital St André

Bordeaux, , France

Institut Bergonié

Bordeaux, , France

Centre François Baclesse

Caen, , France

Centre Jean Perrin

Clermont-Ferrand, , France

Centre Georges François Leclerc

Dijon, , France

Centre Hospitalier de Versailles

Le Chesnay, , France

Centre Hospitalier Universitaire de Lille - Hôpital Claude Huriez

Lille, , France

Centre Oscar Lambret

Lille, , France

Centre Hospitalier Universitaire DUPUTRYEN

Limoges, , France

Centre Léon Bérard

Lyon, , France

Centre Hospitalier Universiariare Lyon, Hôpital Lyon Sud

Lyon, , France

Institut Paoli Calmette

Marseille, , France

Centre Val d'Aurelle

Montpellier, , France

Clinique Valdegour-Centre médical Oncogard

Nîmes, , France

Fondation Hôpital Saint Joseph

Paris, , France

Hopital du Val de Grâce

Paris, , France

Hôpital Européen Georges Pompidou

Paris, , France

Centre Hospilier Universitaire de Poitiers

Poitiers, , France

Institut Jean Godinot

Reims, , France

Centre Eugène Marquis

Rennes, , France

Centre René Gauducheau

Saint-Herblain, , France

Institut de Cancérologie de la Loire

Saint-Priest-en-Jarez, , France

Centre Hospitalier Starsbourg

Strasbourg, , France

Hôpital FOCH

Suresnes, , France

Institut Claudius Regaud

Toulouse, , France

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, , France

Institut Gustave Roussy

Villejuif, , France

Countries

France

References

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655.

Reference Type: BACKGROUND

PMID: 17215530 (View on PubMed)

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.

Reference Type: BACKGROUND

PMID: 17215529 (View on PubMed)

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.

Reference Type: BACKGROUND

PMID: 17538086 (View on PubMed)

Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12.

Reference Type: RESULT

PMID: 21664867 (View on PubMed)

Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.

Reference Type: DERIVED

PMID: 37146227 (View on PubMed)

Polena H, Creuzet J, Dufies M, Sidibe A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero JM, Escudier B, Negrier S, Pages G, Vilgrain I. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma. Br J Cancer. 2018 May;118(9):1179-1188. doi: 10.1038/s41416-018-0054-5. Epub 2018 Mar 22.

Reference Type: DERIVED

PMID: 29563634 (View on PubMed)

Other Identifiers

ET2007-035

Identifier Type: -

Identifier Source: secondary_id

TORAVA

Identifier Type: -

Identifier Source: org_study_id